Moxifloxacin: A review of its use in the management of bacterial infections

Drugs

Volumn 64, Issue 20, 2004, Pages 2347-2377

  Keating, Gillian M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATENOLOL; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; GLIBENCLAMIDE; ITRACONAZOLE; LEVOFLOXACIN; MORPHINE; MOXIFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ABDOMINAL PAIN; ARTHROPATHY; BACTERIAL INFECTION; CARDIOTOXICITY; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION PAIN; INSOMNIA; KLEBSIELLA PNEUMONIAE; LIVER DYSFUNCTION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NEUROTOXICITY; NONHUMAN; PHOTOTOXICITY; QT PROLONGATION; REVIEW; SIDE EFFECT; SINUSITIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SYSTEMATIC REVIEW; TASTE DISORDER; TORSADE DES POINTES; VOMITING; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; BRONCHITIS, CHRONIC; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; DNA GYRASE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; QUINOLINES; SINUSITIS; TISSUE DISTRIBUTION;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; MYCOPLASMA; MYCOPLASMA PNEUMONIAE; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 6344290039     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464200-00006     Document Type: Review

References (183)

1. Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002 Feb; 14 Suppl. 2: 22-8
2. Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (3): 234-47
3. Handrail VT. Overview of the fluoroquinolones: focus on moxifloxacin. Hosp Formul 2002; 37 Suppl. 3: 13-5
4. Barman Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000 Jan; 59 (1): 115-39
5. Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 2002; 62 (6): 967-73; discussion 974-5
6. Morrissey I, Colclough A, Viljoen L, et al. The comparative in vitro activity of moxifloxacin against respiratory tract pathogens isolated during 2003 from LIBRA Targeted Surveillance [abstract no. P527 plus poster]. 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1-4; Prague
7. Dalhoff A. Dissociated resistance among fluoroquinolones [abstract]. Anti-Infect Drug Chemother 1998; 16 Suppl. 1: 75
8. Kubitza D, Delesen H. Influence of oral moxifloxacin on the QTc interval of healthy volunteers [abstract no. 811]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
9. Hollister AS, Haverstock D, Choudhri S. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concomitant QTc prolonging drugs [abstract no. 818], 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
10. Choudhri SH, Haverstock D, Kruesmann F. Safety of concomitant treatment with moxifloxacin and selective serotonin reuptake inhibitors [abstract no. 4]. Pharmacotherapy 2002 Oct; 22 (10): 1324
11. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000 May; 45 (5): 583-90
12. Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy 2001; 21 (10 Suppl. II): 224S-32S
13. Florea NR, Tessier PR, Zhang C, et al. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1215-21
14. Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001 Mar 15;32 Suppl. 1: S64-71
15. Bayer Pharmaceuticals Corporation. AVELOX® (moxifloxacin hydrochloride) tablets and AVELOX® I.V. (moxifloxacin hydrochloride in sodium chloride injection): prescribing information [online]. Available from URL: http://www.bayerus.com [Accessed 2004 Jun 29]
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement. Wayne (PA): National Committee for Clinical Laboratory Standards, 2004. Report no: M100-S14 (M7)
17. Hardy D, Amsterdam D, Mandell LA, et al. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. Antimicrob Agents Chemother 2000 Mar; 44 (3): 802-5
18. Noviello S, Ianniello F, Leone S, et al. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 2003 Nov; 52 (5); 869-72
19. Speciale A, Musumeci R, Blandino G, et al. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. Int J Antimicrob Agents 2002 Feb; 19(2): 111-8
20. Jones ME, Staples AM, Critchley I, et al. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influence: a European multi-centre study. Diagn Microbiol Infect Dis 2000 Jul; 37: 203-11
21. Johnson AP, Warner M, George RC, et al. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales. J Antimicrob Chemother 2001 Apr; 47(4); 411-5
22. Dorai-John T, Thomson CJ, Amyes SGB. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom. J Chemother 2002 Feb; 14 (1); 19-24
23. Liebowitz LD, Slabbert M, Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. J Clin Pathol 2003 May; 56 (5): 344-7
24. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000 Feb; 14 (1): 45-50
25. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002 May; 46 (5): 1295-301
26. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001 Jun; 45 (6): 1721-9
27. Critchley IA, Sahm DF, Thornsberry C, et al. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002 Feb; 42 (2): 129-35
28. Deshpande LM, Jones RN. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). Diagn Microbiol Infect Dis 2000 Jun; 37 (2): 139-42
29. Jones ME, Staples AM, Critchley I, et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother 2000 Oct; 44 (10): 2645-52
30. Betriu C, Redondo M, Palau ML, et al. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother 2000 Jul; 44 (7): 1838-41
31. Pérez-Trallero E, García-Rey C, Martín- Sánchez AM, et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumonias with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2665-7
32. Johnson AP, Warner M, Livermore DM. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. Int J Antimicrob Agents 2001 May; 17 (5): 377-81
33. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000 Jan; 45 (1): 31-9
34. Athamna A, Massalha M, Athamna M, et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 2004 Feb; 53 (2): 247-51
35. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004 Mar; 48 (3): 1012-6
36. Jonas D, Engels I, Friedhoff C, et al. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001 Feb; 47 (2): 147-52
37. Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and β-lactams. Int J Antimicrob Agents 2002 Nov; 20 (5): 366-74
38. Ackermann G, Schaumann R, Pless B, et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000 Mar; 19 (3): 228-32
39. Rodríguez JC, Cebrián L, Lopez M, et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. S Antimicrob Chemother 2004 Mar; 53 (3): 441-4
40. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003 Dec 1; 168 (11): 1342-5
41. Scheid WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9 (1): 1-9
42. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (1): 13-59
43. Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new flurorquinolone. Antimicrob Agents Chemother 1997 Jan; 41 (1): 101-6
44. Klugman KP, Capper T. Concentration-dependent killing of antibiotic resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother 1997; 40: 797-802
45. Esposito S, Noviello S, Ianniello F. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens. Chemotherapy 2000; 46 (5): 309-14
46. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother 1997 Jun; 41 (6): 1377-9
47. Boswell FJ, Andrews JM, Wise R, et al. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 Suppl. B: 43-9
48. Boswell FJ, Andrews JM, Jevons G, et al. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002 Oct; 50 (4): 495-502
49. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10: 23-30
50. Stein GE, Schooley S, Tyrrell KL, et al. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1308-12
51. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologie and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000 Mar; 20 (3): 245-56
52. Weigel LM, Anderson GJ, Facklam RR, et al. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001 Dec; 45 (12): 3517-23
53. Zhanel GG, Walkty A, Nichol K, et al. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003 Jan; 45 (1): 63-7
54. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001 Mar 15; 32 Suppl. 1: S16-22
55. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003 Aug; 47 (8): 2606-14
56. Houssaye S, Gutmann L, Varon E. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2712-5
57. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002 Feb; 46 (2): 522-4
58. Ince D, Zhang X, Hooper DC. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1410-5
59. Schmitz F-J, Hofmann B, Hansen B, et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 481-4
60. Garrison MW, Schimmels JA, Madaras-Kelly KJ. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn Microbiol Infect Dis 2003 Dec; 47 (4): 587-93
61. Piddock LJV, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998 Nov; 42 (11): 2956-60
62. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002 Mar; 46 (3): 680-8
63. Schmitz FJ, Fischer A, Boos M, et al. Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitts, Streptococcus sanguis, and Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2001; 20 (3): 219-22
64. Rodriguez JC, Llinares F, Royo G. In vitro development of resistance to three quinolones in Streptococcus pneumoniae. Chemotherapy 2001 Jan-Feb; 47 (1): 39-42
65. Mayer S, Boos M, Köhrer K. In vitro development of resistance to newer fluoroquinolones in Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin. Eur J Clin Microbiol Infect Dis 2001 Apr; 20 (4); 288-91
66. Blondeau JM, Zhao X, Hansen G, et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001 Feb; 45 (2): 433-8
67. MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J Antimicrob Chemother 2000; 46 (2): 163-70
68. Esposito S, Noviello S, Ianniello F. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model. J Chemother 2000 Dec; 12 (6): 475-81
69. Kays MB, Denys GA. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn Microbiol Infect Dis 2001 Aug; 40 (4): 193-8
70. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001 Jun; 47 (6): 811-8
71. Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001 Mar 15; 32 Suppl. 1: S33-8
72. MacGowan AP, Bowker KE, Wootton M, et al. The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model. Clin Microbiol Infect 1999 Apr; 5 (4): 195-200
73. MacGowan AP, Bowker KE, Wootton M, et al. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield groups A and G. J Antimicrob Chemother 1999 Dec; 44 (6); 761-6
74. Odenholt I, Löwdin E, Gustafsson I, et al. Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Antimicrob Agents Chemother 2002 Jun; 46 (6): 2046-8
75. Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001 Jun; 47 (6): 875-7
76. Wright DH, Gunderson BW, Hovde LB, et al. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob Agents Chemother 2002 May; 46 (5); 1561-3
77. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001 Jun; 45 (6): 1654-9
78. Zhanel GG, Roberts D, Waltky A, et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002 May; 49 (5): 807-12
79. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003 Apr; 22 (4); 203-21
80. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 51-9
81. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003 Sep 1; 52: 616-22
82. Xuan D, Zhong M, Mattoes H, et al. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrob Agents Chemother 2001 Mar; 45 (3): 794-9
83. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003 Apr; 73 (4): 292-303
84. + channel HERG. Mol Pharmacol 2001 Jan; 59 (1): 122-6
85. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58 Suppl. 2: 37-42
86. von Keutz E, Schlüter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 1999; 43 Suppl. B: 91-100
87. Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance [abstract no. P1380]. Clin Microbiol Infect 2002 Apr; 8 Suppl. 1: 323-324 plus poster presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases; 2002 Apr 21-24; Milan
88. Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance [abstract no. P1380]. Clin Microbiol Infect 2002 Apr; 8 Suppl. 1: 323-324 plus poster presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases; 2002 Apr 21-24; Milan
89. Jeffrey AM, Shao L, Brendler-Schwaab SY, et al. Photochemical mutagenicity of phototoxic and photochemically carcinogenic fluoroquinolones in comparison with the photostable moxifloxacin. Arch Toxicol 2000 Nov; 74 (9): 555-9
90. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20 (4): 289-302
91. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83-90
92. Lettieri J, Vargas R, Agarwal V, et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 19-25
93. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 33-8
94. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: the pharmacokinetic standpoint. Chemotherapy 2001; 47 Suppl. 3: 24-31
95. Stass H, Kubitza D, Schühly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40 Suppl. 1: 1-9
96. Burkhardt O, Borner K, Staß H, et al. Single-and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis 2002; 34 (12): 898-903
97. Wise R, Andrews JM, Marshall G, et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999 Jun; 43 (6): 1508-10
98. Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998 Aug; 42 (8): 2060-5
99. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999 Nov; 43 (11): 2793-7
100. Stass H, Stab H, Kruesmann F. Population pharmacokientics of moxifloxacin intravenous in healthy subjects and patients with community-acquired pneumonia [abstract no. O175]. Clin Microbiol Infect 2002 Apr; 8 Suppl. 1: 24
101. Breilh D, Jougon J, Djabarouti S, et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003 Dec; 15 (6): 558-62
102. Gehanno P, Darantière S, Dubreuil C, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002 May; 49 (5): 821-6
103. Leone M, Albanèse J, Sampol-Manos E, et al. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004 Feb; 48 (2): 638-40
104. Müller M, Staß H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartements in humans. Antimicrob Agents Chemother 1999 Oct; 43 (10): 2345-9
105. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999 Dec; 44 (6): 835-8
106. Joukhadar C, Stass H, Müller-Zellenberg U, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3099-103
107. Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today 2000; 36 (4): 229-44
108. Sullivan JT, Lettieri JT, Liu P, et al. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40 Suppl. 1: 11-8
109. Tanaka T, Yoshikawa K, Orii Y, et al. Interethnic difference in the pharmacokinetics of a novel quinolone antibiotic, BAY 12-8039 (moxifloxacin) and estimations of its clinical dose [abstract]. Rinsho Yakuri 1999 Jan; 30: 231-2
110. Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002 Mar; 53 (3): 232-7
111. Stass HH, Dammer S, Kubitza D, et al. No dose adjustment is needed for patients undergoing hemodialysis receiving oral moxifloxacin [abstract no. A-1383]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
112. Stass HH, Dammer S, Kubitza D, et al. Influence of continuous ambulatory peritoneal dialysis on the kinetics of oral moxifloxacin [abstract no. A-1384]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
113. Stass H, Kubitza D, Wensing G. Pooled analysis of pharmacokinetics, safety and tolerability of single oral 400mg moxifloxacin (MFX) doses in patients with mild and moderate liver cirrhosis (LC) [abstract no. 2269]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
114. Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 27-32
115. 2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 39-48
116. Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet 2001; 40 Suppl. 1:57-62
117. Stass H, Schühly U, Möller JG, et al. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 49-55
118. Shain CS, Whitaker AM, Amsden GW. Effects of oral contraceptives on the pharmacokinetics of moxifloxacin in premenopausal women. Clin Drug Invest 2002; 22 (7): 429-34
119. Staß H, Nagelschmitz J, Moeller JG, et al. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther 2004 Jan; 42 (1): 23-9
120. Stass H, Sachse R. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 71-6
121. Hollister AS, Agarwal V, Dain B, et al. Absence of drug interaction between oral moxifloxacin and intramuscular morphine sulfate in healthy volunteers. Clin Drug Invest 2001; 21 (1): 79-85
122. Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet 2001; 40 Suppl. 1: 63-70
123. Müller FO, Hundt HKL, Muir AR, et al. Study to investigate the influence of 400 mg BAY 12-8039 (M) given once daily to healthy volunteers on PK and PD of warfarin (W) [abstract no. A-13]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego
124. Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001 Mar 15; 32 Suppl. 1: S47-50
125. Horstmann R, Delesen H, Dietrich H, et al. No drug-drug interaction between moxifloxacin and β-acetyldigoxin [abstract no. 604]. J Clin Pharmacol 1998 Sep; 38 (9): 879
126. Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000 Jan; 94 (1): 18-27
127. DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000 Nov; 94 (11): 1029-37
128. Hautamaki D, Bruya T, Kureishi A, et al. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Ther Trends 2001; 19(2): 117-36
129. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999 Oct; 44 (4): 501-13
130. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004 Mar 12; 125 (3): 953-64
131. Grassi C, Casali L, Curti E, et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002 Dec; 14 (6): 597-608
132. Kreis SR, Herrera N, Golzar N, et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Manage 2000 Dec; 7 (12): 33-7
133. Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29 (4): 314-28
134. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004 Feb; 23 (2): 129-37
135. Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001 Feb; 14 (2): 52-9
136. File Jr TM, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Today's Ther Trends 2001; 19 (4): 251-70
137. Beecroft MD, Herman-Gnjidic Z, Poulin-Costello M, et al. Moxifloxacin in ambulatory pneumonia (MAP): clinical efficacy and safety of moxifloxacin in Canadian patients [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8): A781
138. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999 Nov; 16 (11): 748-63
139. Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001 Jul; 95 (7): 553-64
140. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001 Jan; 119 (1): 185-95
141. Torres A, Muir JF, Corns P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003 Jan; 21 (1): 135-43
142. Weite T, Bauer T. Treatment with sequential intravenous/oral moxifloxacin was asscociated with faster clinical improvement and earlier discharge from hospital in CAP patients requiring initial parenteral therapy compared with standard therapy [abstract no. O373]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 72-72 plus oral presentation at the 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1-4; Prague
143. Weite T, Bauer T. Treatment with sequential intravenous/oral moxifloxacin was asscociated with faster clinical improvement and earlier discharge from hospital in CAP patients requiring initial parenteral therapy compared with standard therapy [abstract no. O373]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 72-72 plus oral presentation at the 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1-4; Prague
144. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob
145. Fogarty C, Larsen S, Jackson T, et al. Sequential intravenous to oral moxifloxacin monotherapy for community-acquired pneumonia [abstract no. 147]. Pharmacotherapy 2002 Oct; 22 (10): 1349
146. Portier H, Zuck P, Garre M, et al. Moxifloxacin (MXF) versus amoxiciallin/clavulanate (AMX/CA) + roxithromycin (RXT) in community-acquired pneumonia (CAP) adults with risk factors [abstract no. L-1594 plus poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
147. Lode H, Grossman C, Choudri S, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community acquired pneumonia. Respir Med 2003; 97: 1134-42
148. Larsen S, Choudhri S, Haverstock D, et al. Efficacy and safety of sequential (IV to PO) moxifloxacin for treatment of community-acquired pneumonia due to atypical pathogens [abstract no. L-865]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago
149. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003 Aug; 124(2): 526-35
150. Drummond M, Chancellor J, Duprat-Lomon I, et al. Moxifloxacin in hospital treatment of community-acquired pneumonia: a cost-effectiveness analysis across four European countries. EJHP 2004; 1:67-75
151. Baz MN, Jannetti W, Villanueva C, et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Ther Trends 1999; 17(4): 303-19
152. Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillay sinusitis. Clin Ther 1999 Oct; 21 (10): 1664-77
153. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000 Apr; 94 (4): 337-44
154. Klossek JM, Siegert R, Nikolaidis P, et al. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003 Jan; 117 (1): 43-51
155. Rakkar S, Roberts K, Towe BF, et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001 Jun; 55 (5): 309-15
156. Leal del Rosal P, Fabian G, Vick-Fragoso R, et al. Efficacy and safety of moxifloxacin (MXF) vs cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI) [abstract no. 1076]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Diego
157. Leal del Rosal P, Martinez R, Fabian G, et al. Efficacy and safety of moxifloxacin vs cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (USSSI) [abstract no. P493]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 148
158. Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000 Oct; 54 (8): 497-503
159. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 (7): 940-50
160. Iannini PB. General safety of moxifloxacin. Hosp Formul 2002; 37 Suppl. 3: 32-5
161. Data on file, Bayer, 2004
162. Gavin JR, Kubin R, Choudri S, et al. Moxifloxacin and glucose homeostasis. Drug Saf 2004; 27 (9): 671-85
163. European Agency for Evaluation of Medicinal Products. Avelox 400 mg tablets: prescribing information [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Mar 22]
164. Sahm DF, Weaver MK, Ramm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002-2003) surveillance study [abstract no. 201]. 41st Annual Meeting of the IDSA; 2003 Oct 9-12; San Diego
165. Cunha BA. Penicillin resistance in pneumococcal pneumonia: antibiotics with low resistance potential are effective and pose less risk. Postgrad Med 2003; 113 (1): 42-54
166. Bantar C, Bavestrello L, Curcio D, et al. Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American working group (ConsenSur). J Chemother 2002; 14 Suppl. 4: 1-22
167. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 Dec 1; 37: 1405-33
168. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001 Dec; 56 Suppl. 4: IV1-64
169. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31 (2): 383-421
170. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1730-54
171. Ball P. Acute exacerbations of chronic bronchitis. Curr Opin Infect Dis 2000; 13 (2): 171-6
172. European Study on Community-acquired Pneumonia (ESOCAP) Committee. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-91
173. Baiter M, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbation of chronic bronchitis. Can Respir J 2003; 10 Suppl. B: 3B-32B
174. Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? Drugs & Aging 2001; 18(1): 1-11
175. Brook I, Gooch III WM, Reiner SA, et al. Medical management of acute bacterial sinusitis: recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol 2000; 109 Suppl.: 2-20
176. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis 2004. Otolaryngol Head Neck Surg 2004 Jan; 130 (1 Suppl.): 1-45
177. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol 2002; 3 (1): 37-46
178. Ball P. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost? Int J Antimicrob Agents 2000 Nov; 16 (3): 263-72
179. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003 Nov 1; 37(9): 1210-5
180. Genesoft Pharmaceuticals. FACTIVE® (gemifloxacin mesylate) tablets: prescribing information [online]. Available from URL: http://www.factive.com [Accessed 2004 Apr 6]
181. Bristol-Myers Squibb Company. Tequin® (gatifloxacin) tablets and injection: prescribing information [online]. Available from URL: http://www.bms.com [Accessed 2004 Apr 6]
182. European Agency for the Evaluation of Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]. Available from URL: http://www.emea.eu.int/pdfs/human/swp/098696en.pdf [Accessed 2004 Mar 29]
183. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Suppl. II): 253S-72S